Moderna’s Combined Covid and Flu Vaccine Shows Promise
Moderna’s phase 3 clinical trial for its combined Covid and flu vaccine, involving over 8,000 adults aged 50 and older, demonstrated higher antibody levels against both viruses compared to existing standalone vaccines. The trial found antibody responses were 20% to 40% higher, indicating a potentially stronger protection, although side effects like fever were more common. Despite the positive results, regulatory approval from the FDA is not anticipated until 2026, amid ongoing vaccine hesitancy and potential new regulatory requirements.
Loading PerspectiveSplit analysis...
